An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.
Vaccinex announced topline data from the early manifest treatment arm of the company’s Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease (HD).
A study of more than a thousand former professional soccer players has uncovered significantly more deaths from brain disease than among non-players.
Hearing loss in middle age is associated with higher odds of cognitive decline and dementia in later years, suggests a large study in Taiwan.
Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.
